Jiangmen

Researchers are evaluating the effectiveness and safety of Weifuchun tablet in treating gastric intestinal metaplasia in adults who do not have Helicobacter pylori infection. The study aims to determine whether Weifuchun tablet can promote the regression of this condition compared to folic acid, following guidelines from the Chinese consensus on managing gastric precancerous conditions. It is a Phase 4, open-label, randomized controlled trial involving adults aged 18 to 75 years old. Participants are randomly assigned to one of two groups one group takes Weifuchun tablets at a dose of 1400 mg three times daily, while the other group takes folic acid tablets at 5 mg three times daily. Both treatments are taken orally every day for 6 months. Participants visit the clinic every 4 weeks for checkups, symptom evaluation, and to receive their medication supply. During the study, participants undergo regular assessments including upper gastrointestinal endoscopy and histopathological examinations to monitor the regression or progression of gastric intestinal metaplasia and gastric atrophy based on OLGIM and OLGA stages. Researchers measure outcomes from enrollment to the end of the 6-month treatment. Safety and side effects are also monitored throughout the trial, which lasts for the full 6 months of treatment.

Liver failure is a serious condition caused by various factors such as viral infections, alcohol use, drug effects, and blood flow problems, often accompanied by damage to other organs and a high risk of death. This research aims to build a real-world database of hospital patients with liver failure across multiple centers in China. The study will investigate clinical features, infection patterns, the role of muscle loss on patient outcomes, and ways to improve treatments like antiviral therapy and artificial liver support. The findings will support future studies addressing complications and early warning signs in critically ill liver failure patients. The study groups include patients with acute liver failure ALF, subacute liver failure SALF, and acute-on-chronic liver failure ACLF, defined by timing and liver disease history. Data will be collected using an electronic system from hospitalized patients fitting these categories, without administering experimental treatments since this is an observational registry. Participants will undergo clinical data collection during their hospital stay, focusing on symptoms, liver enzyme levels, bleeding risk, infections, and muscle condition. Researchers will measure survival rates at 28 and 90 days and track disease progression up to 48 weeks after discharge. This ongoing monitoring aims to better understand liver failure outcomes and improve care strategies over time.